Chronic low-back pain: pooled results need reconciliation · Review · 2023
Does shockwave help chronic low-back pain and daily function?
In this review of 12 trials (632 people), pain scores were about 1 point lower with shockwave than with comparison treatments at 4 weeks. In the 5 trials that went on to 12 weeks, pain was still lower on average with shockwave. Disability scores were also a little lower at both times.
Helped a little more than comparison care at 4 weeks- trials
- 12
- adults with long-lasting low-back pain
- 632
- weeks: the longest follow-up pooled
- 12
Good to know: Trials varied in devices, doses and comparisons; results were pooled at 4 and 12 weeks.
Liu K, Zhang Q, Chen L, et al. J Orthop Surg Res, 2023 · Read the paper ↗
How this study worked
What happened
- studies
- 12
- people
- 632
- Compared with
- Exercise, physical therapies, trigger-point injections, medicines, myofascial treatment or sham with exercise, depending on the trial
Low-back pain compared with other treatments
Difference in pain-scale points · below zero means less pain with shockwave
Show the numbers
| Difference (pain-scale points) | likely range | |
|---|---|---|
| Pain at 4 weeks | −1.04 | −1.44 to −0.65 |
What the trials used
- Protocol variety
- Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.
Who took part
632 adults with long-lasting low-back pain from muscle, joint or other mechanical causes; people after surgery, during pregnancy or with serious spine disease were excluded.
Side effects
Seven trials reported no side effects and five did not record them. No serious problems were reported.
All the numbers and the full appraisal
The results, in numbers.
Adults with mechanical chronic low-back pain; varied causes included quadratus-lumborum trigger points and sacroiliac pain. Total 318 ESWT/314 controls, but outcome-specific totals differ. Postoperative, pregnancy and specific serious spinal disorders excluded.
Pain at 4 weeks1 reported outcome
Pain at 4 weeks
Pain at 4 weeks VAS points
ESWT versus study-specific controls
12 studies · 632 participants in this estimate · I²=86%
Pooled random-effects estimate
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
Analysis details and source
Figure 3 reverses Guo/Taheri sample sizes relative to Table 1; the Jin 2017 report is nonrandomized despite the RCT label.
Pain at 12 weeks1 reported outcome
Pain at 12 weeks
Pain at 12 weeks VAS points
ESWT versus study-specific controls
5 studies · 230 participants in this estimate · I²=87%
Figure labels fixed effects; text claims random effects.
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
Analysis details and source
Figure 4 labels fixed effects despite text claiming random effects; I²=87%. The review's own sensitivity plot for these five trials (Fig. 8a) is centered on −1.31 with limits −2.70 and 0.09, an interval that crosses zero; a random-effects re-analysis of the Fig. 4 trial data gives the same values. The stored −0.85 (−1.30 to −0.41) is the printed fixed-effect result.
ODI at 4 weeks1 reported outcome
ODI at 4 weeks
ODI at 4 weeks ODI points
ESWT versus study-specific controls
10 studies · 513 participants in this estimate · I²=96%
Pooled random-effects estimate
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
Analysis details and source
Figure/text p=.01 differs from abstract p<.001; I²=96%.
ODI at 12 weeks1 reported outcome
ODI at 12 weeks
ODI at 12 weeks ODI points
ESWT versus study-specific controls
4 studies · 139 participants in this estimate · I²=56%
Pooled random-effects estimate
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
Analysis details and source
Substantial heterogeneity (I²=56%) and only four reports limit precision and generalizability.
Mental health1 reported outcome
Mental health
Mental health standard deviations
ESWT versus study-specific controls
5 studies · 405 participants in this estimate · I²=96%
Pooled random-effects estimate
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
Analysis details and source
Opposing scale directions are not transparently harmonized; I²=96% and the confidence interval crosses zero.
Important null subgroups1 reported outcome
Important null subgroups
Qualitative finding
Pain vs trigger-point injection at 4 weeks MD −0.99 [−2.36, 0.38], p = 0.16; ODI vs physiotherapy at 4 weeks MD −2.35 [−10.89, 6.18], p = 0.59; ODI vs myofascial therapy at 4 weeks MD 3.30 [−0.56, 7.16], p = 0.09.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.
Seven studies explicitly reported no adverse reactions; five did not record them. No serious event was reported, but nonreporting cannot establish safety or no increased risk.
High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.
Source-linked critical reading
clinical synthesis
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.
The review reports modest average pain and disability differences, but important analysis problems reduce confidence. Mental-health benefit was not demonstrated.
How does ESWT compare with other care for chronic low-back pain, disability and mental health?
Review of 12 reports labelled RCTs, 632 participants, four databases to 25 April 2023; PROSPERO CRD42023421589. Pooling selected observations nearest 4 and 12 weeks. Design labels and analytic consistency require verification.
Adults with mechanical chronic low-back pain; varied causes included quadratus-lumborum trigger points and sacroiliac pain. Total 318 ESWT/314 controls, but outcome-specific totals differ. Postoperative, pregnancy and specific serious spinal disorders excluded.
Focused, radial and a low-frequency vibrotherapy device were combined. Table 1 regimens range from 1,000–4,000 pulses, 0.01–0.2 mJ/mm² where given, mostly weekly or twice-weekly courses; one report also gives pressure (2.5 bar) and one gives only a frequency range (15–42 Hz). No single dose follows from this review.
Exercise, physical modalities, trigger-point injection, oral medicines and myofascial treatment; some trials used sham plus shared exercise. These control strategies are not interchangeable.
Pain VAS and ODI at 4/12 weeks; SF-36, PHQ-9 or BDI pooled as mental health at 4 weeks. Higher-is-better and lower-is-better scales require direction harmonization not transparently demonstrated.
Pain MD −1.04 (95% CI −1.44 to −.65) at 4 weeks and −.85 (−1.30 to −.41) at 12 weeks. ODI −4.22 (−7.55 to −.89) and −4.51 (−8.58 to −.44). Mental health SMD 1.17 (−.10 to 2.45), p=.07. Injection subgroup pain and physiotherapy subgroup ODI were null.
Seven studies explicitly reported no adverse reactions; five did not record them. No serious event was reported, but nonreporting cannot establish safety or no increased risk.
High heterogeneity, English-only selection and source-data concerns. Figure 4 uses fixed effects despite 87% heterogeneity and text claiming random effects; the review's own sensitivity plot for those five trials (Fig. 8a) is centered on −1.31 (−2.70 to 0.09), an interval that crosses zero. Figure 3 swaps Guo/Taheri sample sizes versus Table 1. The “Jin 2017” row matches Hong’s retrospective preference-based QL study, not a randomized trial. ODI 4 weeks p=.01 in figure/text differs from abstract p<.001. RoB2 is described with older seven-domain criteria. The GRADE table (Additional file 1) was not in the local intake; the Discussion rates the pain evidence moderate and the ODI evidence low. Academic/provincial funding; no conflicts declared.
Possible short-term benefits require reanalysis with verified trial identity and consistent models. The review cannot establish durable benefit, optimal modality or a mental-health effect.
Reconcile trial labels and denominators, remove nonrandomized reports from RCT-only synthesis, harmonize mental-health scales and prespecify outcome timepoints and models.
Read the original article.
Efficacy and safety of extracorporeal shockwave therapy in chronic low back pain: a systematic review and meta-analysis of 632 patients
Liu K, Zhang Q, Chen L, Zhang H, Xu X, Yuan Z, Dong J. · J Orthop Surg Res · 2023
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →